They take a range of forms and are an increasingly common clinical issue with the growing list of cancers for which the immunologic agents are indicated.
For the first time, the European Society of Cardiology has produced a guideline that, across 272 recommendations, sets out how cardiotoxicity risk can be managed along the cancer treatment pathway.